Amalgamated Bank lessened its position in shares of Elevance Health, Inc. (NYSE:ELV – Free Report) by 3.4% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 47,370 shares of the company’s stock after selling 1,681 shares during the quarter. Amalgamated Bank’s holdings in Elevance Health were worth $25,668,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in ELV. Accretive Wealth Partners LLC acquired a new position in Elevance Health in the 4th quarter valued at about $209,000. ING Groep NV purchased a new stake in Elevance Health in the 4th quarter valued at about $1,119,000. PNC Financial Services Group Inc. grew its holdings in Elevance Health by 1.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 81,298 shares of the company’s stock valued at $38,337,000 after buying an additional 1,226 shares during the period. Gladstone Institutional Advisory LLC grew its holdings in Elevance Health by 3.7% in the 4th quarter. Gladstone Institutional Advisory LLC now owns 1,172 shares of the company’s stock valued at $553,000 after buying an additional 42 shares during the period. Finally, Coldstream Capital Management Inc. grew its holdings in Elevance Health by 0.7% in the 4th quarter. Coldstream Capital Management Inc. now owns 3,471 shares of the company’s stock valued at $1,637,000 after buying an additional 23 shares during the period. Institutional investors and hedge funds own 89.24% of the company’s stock.
Insider Transactions at Elevance Health
In related news, Director Ramiro G. Peru sold 753 shares of the firm’s stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $531.52, for a total transaction of $400,234.56. Following the completion of the transaction, the director now owns 8,744 shares of the company’s stock, valued at $4,647,610.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, CEO Gail Boudreaux sold 34,000 shares of the company’s stock in a transaction on Monday, July 22nd. The stock was sold at an average price of $500.98, for a total transaction of $17,033,320.00. Following the completion of the sale, the chief executive officer now directly owns 126,709 shares of the company’s stock, valued at $63,478,674.82. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Ramiro G. Peru sold 753 shares of the company’s stock in a transaction on Monday, August 5th. The shares were sold at an average price of $531.52, for a total value of $400,234.56. Following the sale, the director now directly owns 8,744 shares of the company’s stock, valued at $4,647,610.88. The disclosure for this sale can be found here. Over the last quarter, insiders sold 35,058 shares of company stock valued at $17,588,116. 0.35% of the stock is currently owned by corporate insiders.
Wall Street Analysts Forecast Growth
Elevance Health Stock Performance
ELV stock opened at $543.25 on Wednesday. The firm has a market cap of $126.26 billion, a P/E ratio of 20.53, a P/E/G ratio of 1.19 and a beta of 0.82. The stock’s 50 day simple moving average is $535.93 and its 200 day simple moving average is $528.70. The company has a current ratio of 1.49, a quick ratio of 1.49 and a debt-to-equity ratio of 0.58. Elevance Health, Inc. has a 12-month low of $431.38 and a 12-month high of $567.26.
Elevance Health (NYSE:ELV – Get Free Report) last issued its quarterly earnings data on Wednesday, July 17th. The company reported $10.12 EPS for the quarter, topping analysts’ consensus estimates of $9.99 by $0.13. The firm had revenue of $43.22 billion during the quarter, compared to the consensus estimate of $42.99 billion. Elevance Health had a return on equity of 20.64% and a net margin of 3.89%. The firm’s revenue was down .4% on a year-over-year basis. During the same period in the prior year, the business earned $9.04 EPS. As a group, equities research analysts predict that Elevance Health, Inc. will post 37.25 EPS for the current year.
Elevance Health Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 25th. Stockholders of record on Tuesday, September 10th will be paid a $1.63 dividend. The ex-dividend date of this dividend is Tuesday, September 10th. This represents a $6.52 annualized dividend and a dividend yield of 1.20%. Elevance Health’s payout ratio is 24.64%.
Elevance Health Company Profile
Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.
Read More
- Five stocks we like better than Elevance Health
- How to Invest in Insurance Companies: A Guide
- Seize the Opportunity: Beyond Meat’s New Steak Could Spark Growth
- Breakout Stocks: What They Are and How to Identify Them
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- What Are Dividend Contenders? Investing in Dividend Contenders
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.